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ABSTRACT
A number of factors influence the development of tolerance,
including the nature, concentration and mode of antigen
presentation to the immune system, as well as the age of the
host.  The studies were conducted to determine whether
immunizing pregnant mice with liposome-encapsulated DNA
vaccines had an effect on the immune status of their offspring.
Two different plasmids (encoding antigens from HIV-1 and
influenza virus) were administered intravenously to pregnant
mice.  At 9.5 days post conception with cationic liposomes,
injected plasmid was present in the tissues of the fetus,
consistent with trans-placental transfer.  When the offspring of
vaccinated dams were immunized with DNA vaccine, they
mounted stronger antigen-specific immune responses than
controls and were protected against challenge by homologous
influenza virus after vaccination.  Moreover, such immune
responses were strong in the offspring of mothers injected with
DNA plasmid 9.5 days after coitus.  These results suggest that
DNA vaccinated mothers confer the antigen-specific immunity
to their progeny. Here we describe the methods in detail as they
relate to our previously published work.
INTRODUCTION
Most vaccines intended for human use are administered to
infants and children. Due to the immaturity of their immune
system, newborns exposed to foreign antigens are at risk of
developing tolerance rather than immunity (2-7).  For example,
if antigen is administered shortly after birth, forbidden clones
can emerge and induce such tolerance (2-7).  A number of
factors influence the development of tolerance, including the
nature, concentration and mode of antigen presentation to the
immune system, as well as the age of the host (8,9).  Over the
past decade, there has been considerable interest in the use of
DNA vaccines to prevent infection by pathogenic viruses,
bacteria and parasites, with phase I clinical trials being initiated
against malaria, HIV-1 and hepatitis B virus.
In the present study, we confirmed that plasmid DNA
administered to pregnant mice could reach the fetus through
the placenta.  This was true both of DNA vaccines encoding
the env gene of HIV-1 as well as those encoding the influenza
virus matrix (M) and nucleoprotein (NP) genes.  Analysis of
the immune response of offspring whose mothers were
immunized with the influenza DNA vaccine indicate that these




We used 6-10-week old BALB/c female mice purchased from
Japan SLC, Inc. (Shizuoka, Japan).  All mice were allowed free
access to sterile food and water.
Viral protein expression plasmids and antibodies
A pME18S-M expression plasmid was constructed with the
pME18S expression vector into which M region cDNA from
influenza virus strain A/PR/8/34 (H1N1) had been inserted
(13).  pME18S empty vector was used as a control plasmid for
A/PR/8/34 challenge.  The expression of the proteins was
confirmed by Western blot analysis (10).  pCMV160IIIB
encoding the env gene of HIV-1 strain IIIB has been described
in detail in our previous report (11).  DNA vaccines of NP
(A/pCMV-V1NP) and HA (V1J-HA (PR8)) genes of the
A/PR/8/34 strain (14-16) were the kind gifts from Drs. J. J.
Donelly and D. Montgomery, Merck Research Lab., West
Point, PA.  To confirm that plasmid DNA was transferred
through the placenta, a lacZ expression plasmid containing a
chicken β-actin promoter was also used.
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Virus Preparation (Protocol I)
Mouse-adapted influenza A/PR/8/34 (H1N1) viruses were used
in this study. Maudin-Darby canine kidney (MDCK) cells were
cultured with Eagle’s minimum essential medium (MEM,
Nissui Corp. Tokyo, Japan) containing 10% FCS at 5% CO2,
37oC.  Viruses were harvested from infected MDCK cells and
titrated according to the plaque formation method.
DNA immunization (Protocol II)
Mothers were injected intravenously (i.v.) with DNA vaccine
before or after coitus.  Preparations containing various doses of
the DNA vaccine were encapsulated into liposomes (12).
Briefly, a 1:1 volume of 6.01 mg/ml 3β[N-(N'N'-
dimethylaminoethane) carbamoyl] cholesterol (DC-Chol) and
5.99 mg/ml dioleoylphosphatidylethanolamine (DOPE) in
chloroform was mixed with an evaporator set at 40oC for 1 hr.
Five volumes of 20 mM HEPES buffer (pH 7.8) was added
into the mixture, mixed and kept at 4oC overnight to
completely dissolve the pellet.  Then, the resultant solution was
sonicated with a Sonifier 250 (Branson, Danbury, CT) set at
output control 2-3; duty cycle 30, for 5 min.  The cationic
liposomes were stocked at 4oC and used within 2-3 months.
Prior to administration, an appropriate amount of DNA in
phosphate-buffered saline (PBS), pH 7.2, was mixed with the
liposome solution at a volume ratio of 1:1.  The pregnant mice
were i.v. administered the DNA vaccine or empty vector on
various days after post conception (p.c.) to assess
immunogenicity.  Six weeks after birth, their offspring were
injected intramuscularly (i.m.) in gastrocnemius muscles with
20-50 µg of the same expression plasmid or the empty vector.
For the influenza virus challenge experiment 50 µg each of
plasmids expressing influenza M and NP protein was
administered into pregnant mice by i.v. route.  The same
amount of DNA plasmids was administered to offspring by
i.m. route.
X-gal staining
Mouse fetus was cut in two and washed with PBS once
followed by incubation at 37oC for 30 min with X-gal staining
buffer (5 mM K4Fe(CN)6·3H2O, 5 mM K3Fe(CN)6, 20 mM
MgCl2, 1 mg/ml X-gal).
FISH analysis (Protocol III)
FISH analysis was performed essentially by the method of El-
Naggar et al. (17).  A 564-bp HIV env region fragment (nt
1569-2133) was amplified from pCMV160IIIB plasmid (10)
using primers (5-ATGTGTAACACCTCAGTCATTAC and
TTATCTTTTTTCTCTCTGCACCAC-3).  The PCR product
was purified from 1.5% agarose gel using QIAquick gel
extraction kit (Qiagen) and was labeled with digoxigenin-11-
dUTP by nick translation.  The labeled product (300-560 bp
DNA) was confirmed on 2% agarose gel and used for a
hybridization probe.  The tissue samples were taken from mice
to which 50 µg of HIV plasmid pCMV160IIIB (11) or
influenza plasmid V1J-HA(PR8) (14) with liposomes were
administered and sliced to prepare histological examination.
The samples were denatured and hybridized with digoxigenin-
labeled probes using a previously described method (17).  After
hybridization, the slides were washed and stained with an anti-
digoxigenin rhodamine (a red fluorochrome: Boehringer
Mannheim, Germany).  The slides were counterstained with
4,6-diamino-2-phenylindole dihydrochloride (DAPI).  Images
were made with a Nikon SA fluorescence microscope (Nikon
Corp., Tokyo, Japan) and a Charge Coupled Device (CCD)
camera interfaced with a Cyto Vision (Applied Imaging,
Sunderland, UK).
Cytokine ELIspot assay (Protocol IV)
The cytokine ELIspot assay was performed with minor
modifications, as previously described (18,19). Briefly, 96-well
microplates (MAIPS4510, Millipore, Bedford, MA) were
coated with anti-mouse IFN-γ rat mAb (PharMingen), and after
adding cells isolated from the spleen 7 days after
immunization, plates were incubated in a 5% CO2 atmosphere
at 37°C with or without 10 µg/ml of V3 peptide.  After a 24-
hour culture, plates were washed and incubated again for 2
hours with biotinylated anti-mouse IFN-γ mAb (PharMingen).
Then, after staining with alkaline phosphatase, the spots in
each well were counted using a computer assisted video image
analysis system (Zeiss Co., Germany).  By applying the proper
dilution factor the total number of cytokine-secreting cells was
calculated.
Virus challenge
Under light diethyl ether anesthesia, the offspring were
simultaneously infected with virus at day 10 after
immunization with the same plasmid DNA as that administered
to their mothers.  Five lethal doses (LD50) of influenza
A/PR/8/34 (H1N1) in 30 µl of PBS were administered by the
intratracheal route using a 24-gauge stainless steel animal
feeding tube (Popper & Sons, New York, NY).  The mortality
rate was determined after 20 days.
Statistical analysis
Statistical analysis for comparison of two groups was
conducted using an unpaired t-test or one-way factorial
analysis of variance (ANOVA) for distribution parameters.
Significance was defined as p<0.05 in both analyses.
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Fig. 1: Gene expression of lacZ in mouse fetus. A and B,
Stained tissue of a fetus cut in two, whose mother received
30 µg of lacZ plasmid with liposomes at day 9.5 postcoitus
(p.c.); C and D, stained tissue of a fetus whose mother
received 30 µg of empty plasmid with liposomes at day 9.5
p.c.
RESULTS
Gene transfer into fetuses
Initial studies examined whether DNA plasmids could be
transmitted through the placenta of pregnant mice.  To evaluate
plasmid uptake and expression in fetal tissue, a plasmid
expressing the lacZ gene was utilized.  To increase the uptake
Fig. 2: FISH analysis.  Vertebra of a fetus whose mother
received HIV plasmid pCMV160IIIB (A) or influenza
plasmid V1J-HA (PR8) (B) with liposomes at day 9.5 p.c.
These samples were reacted with HIV env region fragment
labeled with digoxigenin-11-dUTP, followed by staining
with an antidigoxigenin rhodamine.  Red fluorochrome
indicates the presence of HIV-IIIB DNA.
of this plasmid, it was liposome-encapsulated prior to i.v.
delivery (8).  Tissues from newborn mice from mothers
injected with the lacZ plasmid and liposomes 9.5 days p.c.
showed strong expression of that gene (Fig. 1).  Of particular
interest was the intense staining in the umbilical region of the
fetuses.  Examination by the FISH method confirmed that
abundant plasmid DNA had been transmitted to the fetuses
(Fig. 2).  We found abundant plasmid DNA in spleen, liver,
lung, and other tissues (data not shown).
ELIspot analysis using spleen cells from immunized offspring
of vaccinated mothers was performed (Table 1).  When
stimulated in vitro with vaccine-encoded antigen, a significant
increase in the number of spleen cells secreting IFN-γ was
observed.
Table 1: ELIspot analysis of IFN-γ producing spleen cells
from DNA-vaccinated mice whose mothers had been
injected with the same vaccine during pregnancy.
Immunogen administered to IFN-γ producing cells
Pregnant mothers Progenies  (Spot/106spleen cells)
1. pCMV160IIIB pCMV160IIIB 42.6±9.6*
2. pCMV160IIIB Non-immune 20.6±6.7
3. Empty vector pCMV160IIIB 28.2±3.5*
4. Empty vector Empty vector 16.7±6.3
5. Non-immune Non-immune 13.9±5.9
At day 9.5 p.c., pregnant BALB/c mice were i.v. injected with 50 µg of
pCMV160IIIB or empty vector with liposomes.  Six weeks after birth the
offspring were immunized i.m. with 50 µg of the same plasmid or empty
vector as received by their mothers.  After 7 days, spleen cells were collected
and cocultured with V3 peptide for 24 hours.  Data represent means±SE of 6-8
mice.  *Indicates significant difference (p<0.05) compared to the empty vector
(control).  †Means a significant difference between the two indicated  values.
Data from two other experiments showed similar results.
Challenge test with influenza virus
To examine the immunoprotective effect of maternal
vaccination with a DNA vaccine against influenza virus,
offspring were immunized with 50 µg of the same vaccine at 6
weeks of age.  Seven days later they were challenged with
influenza virus A/PR/8/34.  More than 70% of the offspring of
vaccinated mothers survived (Fig. 3), whereas only 20% of the
offspring of non-vaccinated mothers survived.  All of the non-
immunized offspring whose mothers received liposomes alone
or were not immunized had died.
The timing of maternal DNA vaccination on the capacity of
offspring to develop protective immunity was then examined.
Whereas <20% of normal vaccinated mice (and offspring of
mothers vaccinated 20 days prior to mating) survived
the
 †
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Fig. 3: Protection of offspring against a lethal A/PR/8/34 influenza virus challenge.  Day 9.5 p.c. pregnant BALB/c mice
were i.v. injected with 50 µg each of pME18S-M and pCMV-V1NP with or without liposomes.  Six weeks after birth, their
offspring were immunized i.m. with a total of 50 µg of the same plasmid DNA with liposomes. In one group, offspring of
mothers that had received DNA vaccine with liposomes were not administered vaccine.  In another group, the mother and
progenies received only empty vector.  Non-immunized normal mice were used as the other control.  After 7 days, all mice
were challenged with 5xLD50 of A/PR/8/34 virus.  The percentage of survival of these mice was studied for another 15 days.
n, number of mice.
challenge, >50% of the offspring of immunized mothers
survived (Table 2).
These findings indicate that immunization of mothers with a
DNA vaccine against the influenza virus improves the ability
of their offspring to develop protective immunity against viral
challenge post vaccination.
DISCUSSION
Two independent techniques were used to establish that
plasmid DNA administered to pregnant mice could reach the
fetus.  One is the administration of a β-gal encoding plasmid
which allowed for the direct identification of protein
expression in neonates.  Intense staining of the placenta was
consistent with transplacental migration of the plasmid.  The
other technique is the FISH method which was used to directly
detect plasmid DNA in fetal tissue (Fig. 2).  Our results
confirm and extend the previous finding (10) that in mice a β-
gal plasmid can be transmitted through the placenta to the
fetus.  Of particular importance, we established that such trans-
placental transfer influences the recipients’ subsequent
capacity to mount an immune response against the plasmid-
encoded antigen.  This was manifested by improved cellular
immunity (Table 1) and higher levels of pathogen-specific
protection (Fig. 3 and Table 2).
These studies were also performed to test the hypothesis that
the administration of a DNA vaccine during pregnancy may
induce antigen-specific tolerance in the offspring, as suggested
by the clonal selection theory of Burnet (3,4,20).  Although
pregnant mice were immunized with various doses of several
different DNA vaccines, we found that immunity but not
tolerance was elicited in the fetus (Fig. 3 and Tables 1 & 2).
Using this technique, we did not observe antigen-specific
immune tolerance in progeny as reported by Mor et al. (21).
This could reflect our use of a different plasmid (Mor et al.
detected tolerance following neonatal immunization with a
plasmid encoding the circumsporozoite protein of malaria), or
the very limited amount of plasmid actually transferred trans-
placentally.  Indeed, Ichino et al. demonstrated that neonatal
tolerance was dose-dependent, and could be reliably induced
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only when >10 µg of plasmid was injected into newborn mice
(8).  This is consistent with other reports showing that low dose
antigen can induce immune responsiveness, while high dose
immunization can induce tolerance in young recipients
(9,22,23).  This might be in support of Burnet’s theory that
high levels of neonatal antigen can trigger clonal deletion (4,8).
Table 2: The importance of timing the DNA immunization
of pregnant mothers against A/PR/8/34 virus challenge.
DNA vaccination of Survival after
immunization
Pregnant mothers Progeny Survivors/total
(%)
1. DNA vaccination
20 days before coitus DNA vaccination 3/19 (15.8)
day 5.5 p.c. DNA vaccination 5/20 (25.0)
day 9.5 p.c. DNA vaccination 11/21 (52.3)*
day 14.5 p.c. DNA vaccination 12/19 (63.2)*
day 9.5 p.c. no vaccination 3/18 (16.7)*
2. Empty vector
day 9.5 p.c. DNA vaccination 2/22 (9.1)
3. Non-immune control Non-immune 1/19 (5.3)
Pregnant BALB/c mice were i.v. injected with 25 µg each of A/pCMV-
V1NP+pME18S-M and liposomes on day 5.5, 9.5 or 14.5 p.c.  Six weeks after
birth, all offspring were immunized i.m. with 50 µg of the same plasmid DNA
as received by their mothers.  After 7 days, these mice were challenged with
5xLD50 of A/PR/8/34 and the per cent survival was determined after another
20 days.  Data represent means±SE of 19-22 mice.  *Indicates statistically
significant difference (p<0.05) between non-immune control group.  Data
from another separate experiment showed similar results.
When offspring of vaccinated mothers were immunized at 6
weeks of age with the same DNA vaccine, they displayed
significant anamnestic responses.  Re-immunization was
required, however, since trans-placental transport of plasmid
alone did not trigger strong immune responses in the newborn,
or provide adequate protection from infection (Fig. 3 and Table
2).  On the other hand, re-exposure of these mice to vaccine at
6 weeks of age elicited a strong, protective immune response
characterized by antigen-specific antibody, CTL and cytokine
responses.  The administration of DNA vaccine into amniotic
fluid induced a high level of protective immunity (24).  In the
present study, when DNA vaccine was given to mothers, Ag-
specific acquired immunity was induced in their offspring.
Therefore, this method may be effective in the prevention of
pertussis, hepatitis type B and C, mumps, rubella and various
other infections occurring in infants as well as animals.
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PROTOCOL I: PREPARATION OF INFLUENZA VIRUS
1. Culture MDCK cells (ATCC, No. CCL-34) in a 10 cm2 dish with Minimum Essential Medium (MEM) containing 10% FCS
and antibiotics in a CO2 incubator at 37oC.
2. Aspirate medium from a confluent cell monolayer.
3. Wash cells once with PBS.
4. Remove PBS and infect cells with 1 ml of FCS-free MEM containing 104 pfu of influenza virus.
5. Place in a CO2 incubator at 37oC for 1 hr, rocking the dish at 15-30 min intervals to keep cells moist.
6. After 1 hr of incubation, add 10 ml of MEM medium containing 10% BSA and antibiotics, and place in a CO2 incubator at
37oC for 3 days.
7. Store supernatant at –80oC until use.
Titration of influenza virus
1. Prepare a 6-well tissue culture dish with confluent MDCK cells.
2. Aspirate medium and wash cells once with PBS.
3. Remove PBS and infect cells in duplicate wells with 0.5 ml of the 10-5, 10-6, and 10-7 virus dilutions in FCS-free MEM
medium.
4. Place in a CO2 incubator at 37oC for 1 hr, rocking the dish at 15-30 min intervals to keep cells moist.
5. Before the 1 hr infection is finished, melt 2% low-melt agarose and place in a 45oC water bath to cool.  Be sure it cools to
45oC before using it to overlay cells. Prepare and warm to 45oC MEM medium containing 10%BSA.
6. Mix equal volumes of 2% agarose and the MEM medium from step 5.
7. Aspirate the viral inoculum from the cells (from step 4).  Overlay each well with 2 ml agarose and allow to solidify at room
temperature (RT) or 4oC.  Place in a CO2 incubator at 37oC for 3 days.
8. Remove the agarose and add 0.5 ml of 0.1% crystal violet to each well.  Incubate for 5 min at RT.
9. Aspirate crystal violet and allow wells to dry.
10. Determine the titre by counting plaques within the wells and multiplying by the dilution factor.
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PROTOCOL II: PREPARATION OF LIPOSOME
Materials:
• L-α-phosphatidylethanolamines dioleoyl (DOPE, Avanti Polar-Lipids, Inc.)
• 3β[N-(N' N'-dimethylaminoethane) carbamoyl] cholesterol (DC-Chol, Avanti Polar Lipids, Inc.)
Preparation of 1 ml of Liposome
1. Dissolve DC-chol in chloroform at a concentration of 60.1 mg/10ml and store at –20oC.
2. Dissolve DOPE in chloroform at a concentration of 59.9 mg/10 ml and store at –20oC.
3. Mix 100 µl each of DC-Chol and the DOPE stock solutions.
4. Evaporate it with evaporator with gentle mixing at 40oC.
5. Add 1 ml of HEPES buffer (sterile, pH 7.8) and dissolve the pellet completely with vortex.
6. Hydrate at 4oC for 12 to 72 hrs.
7. Sonicate it at output 2-3, duty cycle 30 (twice for 5 min).
8. Store at 4oC until use.
Synthesis of liposome-DNA mixture
1. Dissolve 5-50 µg of plasmid DNA in 50 µl of PBS.
2. Mix 50 µl of the DNA solution with 50 µl of liposome and pipet several times.
3. Set the liposome-DNA mixture at RT for 15 to 30 min before administration (Do not incubate the DNA with the liposome for
more than 1 hr before administration).
4. Administer 100 µl of liposome-DNA mixture per mouse.
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PROTOCOL III: FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
Probe Preparation
Materials:
• Digoxigenin-11-dUTP (1 nmol/µl, Roche Diagnostics Inc., Mannheim, Germany)
• DNA polymerase I (10 U/µl, GibcoBRL)
• 10 x A4 dNTP mix (Roche Diagnostics Inc., Mannheim, Germany)
• DNA polymerase I (0.5 U/µl)/DNase I (0.4 mU/µl) mix (GibcoBRL)
Probe Labeling
1. Purify PCR product from agarose gel using QIAquick gel extraction kit (Qiagen).
2. Mix following reagents at RT:
a) 10 x A4 dNTP mix, 5 µl
b) PCR DNA, 1 µg
c) Dig-11-dUTP, 1 µl
d) DNA polymerase I, 1 µl
e) DNA polymerase I/DNase I mix, 4.5 µl
f) Make up to 50 µl with H2O
3. Incubate the mixture at 15oC for 50 min.
4. Stop the reaction at 80oC for 10 min.
5. Check the probe on 2% agarose gel (300-560 bp DNA was visible).
Preparation of Specimen Sections
1. Remove the tissue from the animal.
2. Put the tissue in a disposable vinyl specimen mold.
3. Immediately soak specimen mold into liquid nitrogen.
4. Cut block into 10 µm thin sections.
5. Dry slides at RT for 30 min.
6. Wash slides with PBS at RT for 5 min.
7. Incubate slides in 75 mM KCl at RT for 10 min.
8. Soak slides in methanol/acetate acid mix (3 vol:1 vol) at RT for 10 min (to fix tissue).
9. Dry slides at RT for 5 min.
10. Wash slides with PBS at RT for 5 min.
11. Incubate slides with 0.005% trypsin in PBS at 37oC for 15 min (remove protein).
12. Wash slides with PBS twice at 4oC for 5 min.
13. Incubate slides with 10 µg/ml of RNase in SSC (degrades endogenous RNA).
14. Wash slides with PBS twice at RT for 5 min.
15. Incubate slides in 4% PFA at RT for 5 min (fix tissue).
16. Wash slides with PBS twice at RT for 5 min.
17. Incubate slides in 0.1% NP-40/2 x SSC at 37oC for 30 min.
18. Soak slides in 70%, 85% and 100% ethanol at RT for 2 min each (to fix tissue).
Detection with FISH method
Materials:
• RNase: Make 1 mg/ml stock in 2 x SSC. Inactivate DNase by placing in boiling water for 10 min. Freeze in aliquots
suitable for 1:10 dilution.
• 20 x SSC (pH 7.00): 3 M NaCl + 0.3 M Na citrate, pH 7; filter before use.
• Master mix (50% formamide, 2 x SSC):
a) Formamide, 5 ml
b) 20 x SSC, 1 ml
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c) Dextran sulfate, 1 g
d) Must heat for 1-2 hrs to dissolve. Bring to pH 7.0 with HCl.  Bring volume to 7.0 ml with ddH2O.
• Denaturing solution: 70% formamide in 2 x SSC (0.7 volume formamide + 0.1 volume 20 x SSC) pH 7.0 with HCl.
Bring to volume with ddH2O.
• Hybridization wash buffer: Prepare 50% formamide in 2 x SSC (0.5 volume formamide + 0.1 volume 20 x SSC) and
adjust pH to 7.0 with HCl.  Bring to volume with ddH2O.
• 4 x SSC/0.1% Triton X-100:  Dilute 20 x SSC 1:5, adjust pH to 7.0 and then add Triton X-100 to a final concentration of
0.1%.  Autoclave.
• Anti-Digoxigenin-Rhodamine polyclonal antibody (Roche Diagnositic Inc., Mannheim, Germany): Dilute to the final
concentration with 5% skim milk in PBS.
Day 1
1. Mix:
a) Nick product, 40 µl
b) 3 M sodium acetate, 4 µl
c) Salmon sperm DNA (10 mg/ml), 4 µl
d) 100% ethanol, 100 µl
2. Keep at –80oC for 15 min.
3. Centrifuge at 1500 rpm for 30 min in a microcentrifuge.
4. Dry up.
5. Dissolve DNA in 20 µl of a solution containing 70% master mix and 30% ddH2O.
6. Denature probe mixture at 73oC for 5 min.
7. Place on ice.
8. Soak treated tissue slides at 73oC denaturation solution for 5 min.
9. Incubate tissue slides with 70% ethanol for 2 min on ice.
10. Incubate tissue slides with 85% ethanol for 2 min on ice.
11. Incubate tissue slides with 100% ethanol for 2 min at RT.
12. Dry tissue slides on 37oC hot plate.
13. Incubate with denatured probe mixture.
14. Cover the tissue slides with cover glass and seal with paper cement.
15. Incubate tissue slides at 37oC in a moist incubator for 1-3 days.
Day 2
1. Remove paper cement and cover glass.
2. Wash slides three times at 45oC with 50% formamide/2 x SSC for 10 min.
3. Wash slides once at 45oC with 2 x SSC for 10 min.
4. Wash slides once at RT with 2 x SSC for 10 min.
5. Block with 5% skim milk at RT.
6. Incubate slides with anti-Digoxigenin-Rhodamine Ab (1:200 dilution, protected from light in all of the following steps).
7. Wash slides with 4 x SSC at RT for 10 min.
8. Wash slides with 4 x SSC/0.1% Triton X-100 at RT for 10 min.
9. Wash slides with 4 x SSC at RT for 10 min.
10. Wash slides with H2O at RT for 5 min.
11. Dry slides.
12. Counter stain slides with 0.05 µg/ml of 4,6-diamidino-2-phenylindole in PBS.
13. Store slides at –4oC until counting.
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PROTOCOL IV: ELISPOT ASSAY
Materials:
• Blocking solution: RPMI 1640 containing 10% FCS
• Wash buffer: 1 x PBS containing 0.05% Tween-20
• Plate: MultiScreen-IP sterile Plate, Millipore (Cat. No. MAIPS4510)
• Anti-mouse IFN-γ mAb 1 mg/ml (x 100 in PBS) (PharMingen, Cat. No. 554431)
• Biotinylated anti-mouse IFN-g mAb (x 1000 in PBS) (PharMingen)
• Alkaline phosphatase streptavidin (Vector Laboratories, Inc. CA; Cat. No. SA-5100; working solution: dilute 1 µl of
alkaline phosphatase streptavidin in 5 ml of PBS containing 0.05% Tween-20 and 5% BSA just before use)
• BCIP/NBT phosphatase substrate (Kirkegaard & Perry Laboratories, Inc., MD; Cat. No. 50-81-18)
1. Incubate 50 µl/well of 100-fold diluted anti-mouse IFN-γ mAb in PBS to ELIspot IP plate at 4oC overnight.
2. Discard the mAb and wash wells once with 200 µl/well blocking solution.
3. Incubate 200 µl/well blocking solution at RT for 2 hrs.
4. Discard the blocking solution.
5. Add 200 µl/well of 104, 105 or 106 splenocytes with or without antigen 10 µg/ml in RPMI1640 with 10%FCS (each sample
was stimulated in triplicate with or without antigen at each dose).
6. Place the plate in a 37oC-incubator at 5% CO2 for 24 hrs.
7. Discard the cell suspension.
8. Wash wells twice with 200 µl of ddH2O and allow wells to soak for 3-5 min at each wash step.
9. Wash wells three times with 200 µl/well wash buffer.
10. Discard the wash buffer and incubate 100 µl/well of 1,000-fold diluted Biotinylated anti-mouse IFN-γ mAb at RT for 2 hrs.
11. Wash wells three times with 200 µl/well wash buffer.
12. Discard wash buffer and incubate with 50 µl/well of diluted alkaline phosphatase streptavidin at RT for 1-2 hrs.
13. Wash the plate six times with 200 µl of ddH2O containing 0.05% Tween-20.
14. Incubate the plate with 50 µl/well of BCIP/NBT phosphatase substrate at RT for 20 min-1 hr.
15. Wash the plate three times with 200 µl of ddH2O.
16. Dry the plate and count spots with a computer-assisted video image analysis (CVIA) system.
